Vanguard Group’s VITAE PHARMACEUTICALS INC COMMON STOCK VTAE Stock Holding History

Vanguard Group’s Portfolio VTAE Stock Details VTAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-935,064	Closed	-$19.6M	–	4134
2016 Q3	$19.6M	Buy	935,064 +164,576	+21%	+$1.9M	﹤0.01%	2371
2016 Q2	$8.31M	Buy	770,488 +181,223	+31%	+$1.55M	﹤0.01%	2733
2016 Q1	$3.91M	Buy	589,265 +168,162	+40%	+$1.53M	﹤0.01%	3092
2015 Q4	$7.62M	Buy	421,103 +41,144	+11%	+$566K	﹤0.01%	2780
2015 Q3	$4.18M	Buy	379,959 +96,675	+34%	+$1.03M	﹤0.01%	3055
2015 Q2	$4.08M	Buy	283,284 +30,512	+12%	+$414K	﹤0.01%	3107
2015 Q1	$2.96M	Buy	252,772 +125,095	+98%	+$1.69M	﹤0.01%	3243
2014 Q4	$2.13M	Buy	+127,677	New	+$1.87M	﹤0.01%	3264

Vanguard Group's VTAE Position: Q4 2016 in Review

Vanguard Group sold out of VITAE PHARMACEUTICALS INC COMMON STOCK (VTAE) in Q4 2016, closing a stake of 935,064 shares — an estimated $19.6M sold.

Vanguard Group first reported a position in VTAE in Q4 2014 and held it in 8 quarters. The position peaked at $19.6M in Q3 2016. 0 funds tracked by Wall St. Rank hold VTAE as of Q4 2016.

Vanguard Group reported no remaining VITAE PHARMACEUTICALS INC COMMON STOCK position as of Q4 2016 after selling out during the quarter.
Vanguard Group sold 935,064 VITAE PHARMACEUTICALS INC COMMON STOCK shares in Q4 2016, an estimated $19.6M.
Vanguard Group first reported a position in VITAE PHARMACEUTICALS INC COMMON STOCK in Q4 2014 and held it in 8 quarters.
Vanguard Group's VITAE PHARMACEUTICALS INC COMMON STOCK position peaked at $19.6M in Q3 2016.
0 funds tracked by Wall St. Rank held VITAE PHARMACEUTICALS INC COMMON STOCK as of Q4 2016.

Based on Vanguard Group's 13F filing for Q4 2016, filed 14 Feb 2017.